Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 2,196 matching trials from the live ClinicalTrials.gov search.
Filters: "blood pressure" Condition: Hypertension Clear all
Completed Not applicable Interventional

An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension

NCT01037920
View directory record Official record
Conditions
Hypertension
Interventions
Self-affirmation exercise, Control
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
21 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 17, 2026, 8:20 AM EDT
Not yet recruiting Phase 4 Interventional

Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound

NCT07167862
View directory record Official record
Conditions
Preeclampsia, Preeclampsia Postpartum, Preeclampsia Severe or Mild
Interventions
Butterfly iQ3 ultrasound system for determination of postpartum volume status, Oral furosemide, Intravenous furosemide
Diagnostic Test · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Social Forces to Improve Statin Adherence (Study B)

NCT02148523
View directory record Official record
Conditions
Medication Adherence, High Blood Pressure, Diabetes
Interventions
Comparison to peers, Adherence feedback, Electronic pill bottle
Behavioral · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Financial Incentives to Translate ALLHAT Into Practice: A Randomized Trial

NCT00302718
View directory record Official record
Conditions
Hypertension
Interventions
Physician-level financial incentives, Practice-level financial incentives, Physician- and practice-level financial incentives
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
12
States / cities
Birmingham, Alabama • Newington, Connecticut • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 2 Interventional

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

NCT06016972
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
Interventions
Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%), QLS-111 ophthalmic vehicle solution
Drug · Other
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Roswell, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study

NCT00425945
View directory record Official record
Conditions
Hypertension
Interventions
Pine Bark Extract (Flavangenol®)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 17, 2026, 8:20 AM EDT
Terminated Phase 4 Interventional Results available

Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study

NCT01275339
View directory record Official record
Conditions
Aortic Stenosis, LV Remodeling, Hypertrophy
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 17, 2026, 8:20 AM EDT
Completed No phase listed Observational

Validation of a Sensor for Non-Invasive Measurements

NCT03463148
View directory record Official record
Conditions
CHF, Renal Disease, Hypertension
Interventions
Not listed
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 17, 2026, 8:20 AM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 17, 2026, 8:20 AM EDT
Completed No phase listed Observational

Heart Disease in Sickle Cell Anemia

NCT00113152
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 8:20 AM EDT
Completed No phase listed Observational

Bedside Monitoring to Identify Impaired Cerebral Autoregulation in Women with Postpartum Hypertension

NCT05155852
View directory record Official record
Conditions
Preeclampsia, Hypertension in Pregnancy
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 17, 2026, 8:20 AM EDT
Terminated Not applicable Interventional

Hypertension Management in Cancer Patients

NCT03919214
View directory record Official record
Conditions
Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, CLL, Hematopoietic Malignancy
Interventions
Automated Messaging
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 74 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 17, 2026, 8:20 AM EDT
Terminated Not applicable Interventional Results available

Storytelling Intervention for African Americans Living With Hypertension

NCT05594264
View directory record Official record
Conditions
Hypertension
Interventions
HBPStories
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 17, 2026, 8:20 AM EDT
Not listed No phase listed Observational

Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment

NCT01758263
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol, Nebivolol
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 1, 2013 · Synced Oct 17, 2026, 8:20 AM EDT
Terminated Phase 2 Interventional Results available

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

NCT00802893
View directory record Official record
Conditions
Isolated Systolic Hypertension, Endothelial Dysfunction
Interventions
6R-BH4, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional

SupportBP 2.0:Behavioral Science and Enrollment in Remote Monitoring for Hypertension Management

NCT04714398
View directory record Official record
Conditions
Hypertension
Interventions
Opt-In Recruitment, Opt-Out Recruitment
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional

COHERE - COntextualized Care in cHcs' Electronic Health REcords

NCT05022316
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
CDS Tool Access
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 17, 2026, 8:20 AM EDT
Not yet recruiting Phase 2 Interventional

Vascular Intervention Strategies Trial for Alzheimer's

NCT07447206
View directory record Official record
Conditions
Hypertension, Hypercholesterolemia, Dementia Risk Factors
Interventions
Angiotensin Receptor Blockers (ARBs), Hydrophilic Statins or Non-Statin Alternative
Drug
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

NCT01432106
View directory record Official record
Conditions
Hypertension, Metabolic Syndrome
Interventions
Aliskerin/Valsartan and Rampiril
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Group Visits to Improve Hypertension Management

NCT00129493
View directory record Official record
Conditions
Hypertension
Interventions
Group medical visits
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Palo Alto, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Tailored to You (TTY) Pilot Study

NCT05141175
View directory record Official record
Conditions
Hypertension
Interventions
Hypertension medication algorithm, Impedance Cardiography
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

NCT00039975
View directory record Official record
Conditions
HIV Infections, Cardiovascular Diseases, Hypertension
Interventions
Indinavir sulfate, Ritonavir, Amlodipine, Diltiazem HCl
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
9
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 8:20 AM EDT
Withdrawn Phase 2 Interventional

Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure

NCT00598429
View directory record Official record
Conditions
Infant, Newborn, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn, Streptococcal Infections
Interventions
Inhaled Prostaglandin E1
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 1 Interventional

Metro Atlanta Heart Disease Study - II (MAHDS II)

NCT01235702
View directory record Official record
Conditions
African Americans With Hypertension.
Interventions
12-week lifestyle modification
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
21 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 17, 2026, 8:20 AM EDT